阿斯塔山丁通过抑制血小板激活和血液凝固来抑制血栓形成
Lili Zhang1,2, Yadan Luo1, Ningwan Lei1
1Department of Pharmacology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, China.
British journal of pharmacology
|February 17, 2026
概括
亚斯丁 (ASX) 通过抑制血小板激活和血液凝结,有效地预防血栓形成. 这种抗氧化类胡卜素提供了一种新的策略,用于心血管健康和预防血栓形成,而无需过度出血.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 血栓形成是全球主要的死亡原因,源于血小板激活和凝固.
- 阿斯塔克桑 (ASX) 是一种胡卜素,具有对心血管健康有益的抗氧化特性.
研究的目的:
- 系统地调查阿斯塔克桑丁 (ASX) 的抗血栓潜力.
- 阐明ASX抗血栓作用的潜在分子机制.
主要方法:
- 在体内对大鼠和小鼠的研究,以及在体内对人类血小板和肝细胞的研究.
- 网络药理学和免疫阻塞用于识别ASX目标.
- 静脉内显微镜可视化血栓的组成部分.
主要成果:
- 通过抑制ROS和下游信号,ASX减弱了血小板聚合,粘附,扩散和凝块收缩.
- 通过降低肝脏ROS和HNF4α,ASX抑制了内在和外在的凝血.
- ASX在预防动脉和静脉血栓形成方面表现出与阿司匹林相当的疗效,但在不引起过度出血的情况下抑制了血小板和纤维素.
结论:
- 阿斯丁 (ASX) 通过抑制血小板和肝脏ROS以及相关途径,表现出多方面的抗血栓作用.
- 美国证券交易所 (ASX) 提出了一项有前途的新型治疗策略,用于预防血栓形成.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Formation of the Platelet Plug
9.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.8K
Disorders of Hemostasis
2.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.3K
Extrinsic and Intrinsic Pathways of Hemostasis
13.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
13.5K


